U.S. Stock Futures Fall as Nvidia Drops Despite Strong Earnings; Netflix Jumps 9% 
FedEx Faces Class Action Lawsuit Over Tariff Refunds After Supreme Court Ruling 
Australia Housing Market Hits Record High Despite RBA Rate Hike 
Oil Prices Steady as US-Iran Nuclear Talks and Rising Crude Inventories Shape Market Outlook 
Coupang Reports Q4 Loss After Data Breach, Revenue Misses Estimates 
Paramount Skydance to Acquire Warner Bros Discovery in $110 Billion Media Mega-Deal 
Greg Abel’s First Berkshire Hathaway Shareholder Letter Signals Continuity, Caution, and Capital Discipline 
APEX Tech Acquisition Inc. Raises $111.97 Million in NYSE IPO Under Ticker TRADU 
Oil Prices Surge 13% as U.S.-Israel Strikes on Iran Spark Supply Fears 
Ecuador Raises Tariffs on Colombian Imports to 50% Amid Border Security Dispute 
Samsung Electronics Stock Poised for $1 Trillion Valuation Amid AI and Memory Boom 
Netflix Stock Jumps 14% After Exiting Warner Bros Deal as Paramount Seals $110 Billion Acquisition 
Tokyo Core Inflation Slows Below 2%, Complicating BOJ Rate Hike Outlook 
PBOC Scraps FX Risk Reserves to Curb Rapid Yuan Appreciation 
Amazon’s $50B OpenAI Investment Tied to AGI Milestone and IPO Plans 
Flare, Xaman Roll Out One-Click DeFi Vault for XRP Yield via XRPL Wallets 
OpenAI Pentagon AI Contract Adds Safeguards Amid Anthropic Dispute 
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
